Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

MBS314, a GPRC5DxBCMAxCD3 trispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results from a Phase 1 dose escalation study

View Full Paper
Ask AI
Bookmark
Share

Authors

LWLu WenUnion HospitalMWMin WeiNanjing Agricultural University

Discussion

Loading...

Member takes

Overview

Phase I trial reveals MBS314 achieves 63.6% overall response rate in heavily treated multiple myeloma, indicating potential as a therapeutic option.

Key Points

  • To evaluate the safety and efficacy of MBS314, a trispecific antibody, in patients with relapsed/refractory multiple myeloma.
  • Phase I, multicenter, single-arm, open-label trial
  • Eligible patients had relapsed/refractory multiple myeloma with at least 3 prior therapies
  • Dose escalation from 0.3 mg to 120 mg was administered intravenously with step-up dosing.
  • 63.6% overall response rate among treated patients
  • Adverse events primarily included lymphocyte count decrease and cytokine release syndrome
  • Maximum tolerated dose was not reached, indicating a manageable safety profile.

Cite This Study

Wen et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df4ehttps://doi.org/10.1182/blood-2025-2274
View Full Paper
Ask AI
Bookmark
Share